These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11153678)

  • 61. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms.
    Winters MA; Merigan TC
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2575-82. PubMed ID: 15980322
    [No Abstract]   [Full Text] [Related]  

  • 62. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260).
    Demeter LM; Shafer RW; Meehan PM; Holden-Wiltse J; Fischl MA; Freimuth WW; Para MF; Reichman RC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):794-7. PubMed ID: 10681363
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil.
    Pilcher CD; Perkins MD; Fiscus SA; Johnston DM; Dietze R; Duque UH; Zago AM; Assad-Antunes F; Eron JJ
    J Infect Dis; 1999 May; 179(5):1259-63. PubMed ID: 10191233
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients.
    Devereux HL; Loveday C; Youle M; Sabin CA; Burke A; Johnson M
    AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1025-30. PubMed ID: 10933616
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel.
    Wegner SA; Brodine SK; Mascola JR; Tasker SA; Shaffer RA; Starkey MJ; Barile A; Martin GJ; Aronson N; Emmons WW; Stephan K; Bloor S; Vingerhoets J; Hertogs K; Larder B
    AIDS; 2000 May; 14(8):1009-15. PubMed ID: 10853983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
    Kavlick MF; Wyvill K; Yarchoan R; Mitsuya H
    J Infect Dis; 1998 Jun; 177(6):1506-13. PubMed ID: 9607827
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Basic and clinical aspects of drug resistance in human immunodeficiency virus type 1 infection].
    Salomon HE; Pampuro SE; Gu Z; Montaner JS; Libonatti O; Wainberg MA
    Rev Argent Microbiol; 1995; 27(4):214-29. PubMed ID: 8850135
    [No Abstract]   [Full Text] [Related]  

  • 69. Selected topics from the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001. Chicago, Illinois.
    Kuritzkes DR
    HIV Clin Trials; 2001; 2(3):219-26. PubMed ID: 11590531
    [No Abstract]   [Full Text] [Related]  

  • 70. Clinical utility of resistance testing.
    Stebbing J; Gazzard BG
    J HIV Ther; 2002 Nov; 7(4):75-9. PubMed ID: 12733604
    [No Abstract]   [Full Text] [Related]  

  • 71. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.
    Descamps D; Chaix ML; Montes B; Pakianather S; Charpentier C; Storto A; Barin F; Dos Santos G; Krivine A; Delaugerre C; Izopet J; Marcelin AG; Maillard A; Morand-Joubert L; Pallier C; Plantier JC; Tamalet C; Cottalorda J; Desbois D; Calvez V; Brun-Vezinet F; Masquelier B; Costagliola D;
    J Antimicrob Chemother; 2010 Dec; 65(12):2620-7. PubMed ID: 20965891
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Winters MA; Baxter JD; Mayers DL; Wentworth DN; Hoover ML; Neaton JD; Merigan TC
    Antivir Ther; 2000 Mar; 5(1):57-63. PubMed ID: 10846594
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
    Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
    Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant.
    Chetchotisakd P; Anunnatsiri S; Kiertiburanakul S; Sutthent R; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Horsakulthai M; Chasombat S; Ruxrungtham K;
    J Int Assoc Physicians AIDS Care (Chic); 2006 Dec; 5(4):152-6. PubMed ID: 17101807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals.
    Simon V; Vanderhoeven J; Hurley A; Ramratnam B; Louie M; Dawson K; Parkin N; Boden D; Markowitz M
    AIDS; 2002 Jul; 16(11):1511-9. PubMed ID: 12131189
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prevalence of the T215Y mutation in human immunodeficiency virus type 1-infected pregnant women in a New York cohort, 1995--1999.
    Sitnitskaya Y; Rochford G; Rigaud M; Essajee S; Pollack H; Krasinski K; Borkowsky W
    Clin Infect Dis; 2001 Jul; 33(1):e3-7. PubMed ID: 11389511
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients.
    Parkin NT; Deeks SG; Wrin MT; Yap J; Grant RM; Lee KH; Heeren D; Hellmanna NS; Petropoulos CJ
    AIDS; 2000 Dec; 14(18):2877-87. PubMed ID: 11153669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.